Format

Send to

Choose Destination
Cancer Res. 2018 Jul 10. pii: canres.3754.2017. doi: 10.1158/0008-5472.CAN-17-3754. [Epub ahead of print]

Remission of spontaneous canine tumors after systemic cellular viroimmunotherapy.

Author information

1
Unidad de Biotecnología Celular, Instituto de Salud Carlos III.
2
Veterinary Hospital, Alfonso X el Sabio University.
3
Translational Research Laboratory, IDIBELL-Institut Catala d'Oncologia.
4
Servicio de Oncohematología,, Hospital Universitario Niño Jesus.
5
Oncobell and ProCure Programs, IDIBELL-Institut Catala d'Oncologia.
6
Unidad de Biotecnología Celular, Instituto de Salud Carlos III jgcastro@isciii.es.

Abstract

Dogs with spontaneous tumors treated in veterinary hospitals offer an excellent opportunity for studying immunotherapies, including oncolytic viruses. Oncolytic viruses have advanced into the clinic as an intratumorally administered therapeutic; however, intravenous delivery has been hindered by neutralization in the blood. To circumvent this hurdle, mesenchymal stem cells have been used as a "Trojan horse". Here we present the treatment of 27 canine cancer patients with canine mesenchymal stem cells infected with ICOCAV17, a canine oncolytic adenovirus. No significant adverse effects were found. The response rate was 74%, with 14.8% showing complete responses, including total remissions of lung metastasis. We detected virus infection, stromal degeneration, and immune cell infiltration in tumor biopsies after four weeks of treatment. The increased presence of anti-adenoviral antibodies in the peripheral blood of treated dogs did not appear to prevent the clinical benefit of this therapy. These data indicate that oncolytic viruses loaded in mesenchymal stem cells represent an effective cancer immunotherapy.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center